Neurotech is the new blue ocean

Alon Braun

Co-Founder, Neurotech Analytics

Neurotech is the new blue ocean

Longevity.Technology: We were delighted to secure Alon Braun for Longevity2020. As a business architect, he is skilled at helping ideas grow into products, something that is vital in the Longevity sector.

Together with Dmitry Kaminskiy, he founded NeuroTech Analytics and Braun is clear on the importance of neurotech and its ability “to bring big money into Longevity.”

In his video Braun breaks down just what neurotech is and why it is so important. He also explains why early detection of degenerative neurological conditions is so important and the role neurotech has to play.

An interesting point is the one Braun makes about mobility – walking rather than general mobility – and the impact that it has on independence, state-of-mind, and wellness. He points-out that solutions need investment right now to mitigate the burden on healthcare systems and therefore provide valuation ROI to investors.

Braun concludes with an overview that compares the relative failure of pharmacological drugs that attack neurological diseases at the molecular level with technological advances that can take control and even suppress many chronic diseases. He has some statistics to back up his comparison too – find out more in the video!

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Latest articles

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Targeting senescent cells to extend lifespan

Although our understanding of the mechanisms underlying aging is limited, recent findings from animal studies indicate that targeting cellular senescence in vivo may prevent...

At-home wellness biomarker test to deliver instant results

ZiO Health prepares to launch crowdfunding campaign for subscription-based urine test that measures multiple health biomarkers. Biomedical start-up ZiO Health is on a mission to...

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company Roche has bought Dublin-based biotech...